This signaling cascade constitutes an adaptive resistance pathway, the genetic and pharmacological inhibition of which can enhance the efficacy of anti-PD-1 immunotherapy by inhibiting the tumor infiltration of MDSCs (176). This evidence concerns the gene PDCD1 and neoplasm.